My site

NHS Business Services Authority and Taulia win award for Best Fintech Implementation Project Management.

NHSBSA’s Pharmacy Earlier Payment Scheme (PEPS) has accelerated over £1 billion of early payments since July 2018.

SAN FRANCISCO-Friday 2 August 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Working capital solutions provider Taulia and the UK’s NHS Business Services Authority (NHSBSA) have been recognized with a prestigious Bobsguide Partnership Award for the Best Fintech Implementation Project Management. The Bobsguide Partnership Awards showcase the best partnerships in the fintech market, with the judging panel carrying out several rounds of assessment.

Paying pharmacy contractors on time is key to avoiding supply chain disruption and ensuring the British public has access to fully stocked pharmacies. Last year, NHSBSA launched a new Pharmacy Earlier Payment Scheme (PEPS) with Taulia and funding provider Greensill Capit ... Read more »

OSAKA, Japan -Friday 2 August 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO: 4502/NYSE: TAK) today announces that the Takeda Board of Directors has approved key performance indicators (KPIs) to be included in both the company’s short-term and long-term incentive plans for fiscal year 2019, as well as a Special Integration plan designed to promote the successful integration of Shire. The KPIs are designed to align rewards for the CEO, the other senior executives comprising the Takeda Executive Team, as well as key leaders and employees with critical measures of success that focus on the company’s business priorities including the successful integration of Takeda and Shire. Takeda’s fiscal year 2019 KPI framework reflects the feedback received from extensive discussions with shareholders in the first six months following the closing of Takeda’s acquisition of Shire. This KPI framework also alig ... Read more »

OSAKA, Japan -Friday 2 August 2019 [ AETOS Wire ]

• Revenue 849.1 billion yen, up +88.8% versus prior year mainly due to acquisition of Shire, with solid performance of 14 global growth brands
• Strong start with Core Operating Profit* of 283.0 billion, up +142.3% versus FY2018 Q1 and Underlying Core Operating Profit Margin of 32.4%
• Shire integration and synergy capture on track
• Raising full year guidance to reflect divestitures and revised VELCADE Loss of Exclusivity (LOE) assumption

*NOTE: From FY2019 Q1, the term “Core Earnings” has been renamed “Core Operating Profit”. The definitions are identical, only the terminology has changed.

(BUSINESS WIRE)-- Takeda Phar ... Read more »

Visa champions the global fintech community to drive the next generation of digital payments 

VC community supports Fast Track: Visa to automatically qualify portfolio companies of participating VCs into program

SAN FRANCISCO -Friday 2 August 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Fintechs are transforming the global payments ecosystem at a rapid pace, changing the way people invest, manage money, receive loans, and send real-time payments to friends and family. Given the importance of the fintech community, and Visa’s longtime commitment to digital payment innovation, Visa (NYSE: V) today announced the expansion of its popular Fast Track program to the United States in conjunction with a large and growing network of partners.

Fast Track aims to speed up the process of integrating with Visa, to allow nimble start-ups the ability to more easily leverage the reach, capabilities, and security VisaNet, the company’s global payment network, ... Read more »

INGELHEIM, Germany -Friday 2 August 2019 [ AETOS Wire ]

• Sequential afatinib and osimertinib was associated with encouraging time on treatment and overall survival in patients with EGFR T790M-positive NSCLC, especially in patients with Del19 mutation

• Updated analysis of the observational GioTag study is published today in Future Oncology

(BUSINESS WIRE)-- Boehringer Ingelheim today announced updated, interim analysis results from the GioTag study, showing that initiating treatment with afatinib followed by osimertinib provided an overall survival (OS) of almost four years (45.7 months) in patients with Del19-positive tumours.[i] The GioTag study is a real-world retrospective, observational and unblinded study which examined the impact of treatment with Giotrif®/Gilotrif® (afatinib) followed by osimertinib in epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC) patients with acquired T790M mutatio ... Read more »